Publication - Research and analysis
2010/11 Scottish Crime and Justice Survey: Drug Use
This report presents findings from the Scottish Crime and Justice Survey 2010/11 Drug Use module. The report provides information on the experience and prevalence of illicit drug use amongst the general adult population in Scotland.
Table A1.7: % of men aged 16 or over who reported having ever used illicit drugs by age group
Source: SCJS 2010/11. Variable name: QEVE.
| All men % |
16-24 % |
25-44 % |
45-59 % |
60+ % |
|
|---|---|---|---|---|---|
| CLASS A | 15.9 | 24.0 | 26.4 | 12.3 | 1.1 |
| Cocaine | 9.7 | 15.2 | 17.3 | 6.3 | 0.2 |
| Crack | 1.1 | 2.4 | 1.9 | 0.6 | - |
| Ecstasy | 10.1 | 19.6 | 18.1 | 4.1 | * |
| Heroin | 1.2 | 1.4 | 2.0 | 1.2 | 0.1 |
| Methadone | 1.1 | 1.9 | 1.7 | 0.9 | * |
| LSD | 7.5 | 6.2 | 13.4 | 7.7 | 0.5 |
| Magic mushrooms | 7.8 | 8.2 | 13.3 | 7.7 | 0.6 |
| CLASS B | 27.7 | 40.2 | 42.5 | 24.2 | 4.8 |
| Amphetamines | 10.3 | 12.9 | 18.0 | 8.7 | 0.4 |
| Crystal Meth | 0.4 | 0.7 | 0.6 | 0.4 | - |
| Cannabis | 27.0 | 39.4 | 41.2 | 23.6 | 4.8 |
| CLASS C | 7.0 | 12.4 | 11.4 | 4.7 | 0.6 |
| Anabolic steroids | 0.6 | 1.0 | 0.9 | 0.5 | * |
| Ketamine | 1.8 | 4.2 | 3.0 | 0.5 | - |
| Temazepam | 2.9 | 3.3 | 5.4 | 2.4 | - |
| Valium | 5.2 | 9.6 | 8.3 | 3.2 | 0.5 |
| NOT CLASSIFIED | |||||
| Glues/solvents/gas/aerosols | 3.4 | 4.1 | 6.2 | 2.4 | 0.3 |
| Poppers | 9.0 | 16.1 | 15.7 | 4.7 | 0.4 |
| NEW DRUGS | 2.6 | 7.8 | 3.1 | 1.2 | 0.2 |
| BZP | 0.2 | 0.1 | 0.3 | 0.1 | - |
| GBL | 0.3 | 0.2 | 0.7 | 0.2 | - |
| Khat | 0.4 | 0.5 | 0.4 | 0.4 | 0.2 |
| Mephedrone | 1.6 | 7.4 | 1.4 | 0.1 | - |
| Synthetic cannabinoids | 0.6 | 1.2 | 1.1 | 0.4 | * |
| ANY STIMULANTS | 16.3 | 25.3 | 28.2 | 11.4 | 0.8 |
| ANY OPIATES | 1.5 | 2.5 | 2.2 | 1.5 | 0.1 |
| ANY PSYCHEDELICS | 10.9 | 12.8 | 18.3 | 10.2 | 0.9 |
| ANY DOWNERS / TRANQ. | 6.2 | 11.0 | 10.0 | 4.0 | 0.5 |
| ANY DRUGS | 29.2 | 41.6 | 44.5 | 26.0 | 5.4 |
| ANY DRUGS EXCLUDING NEW DRUGS | 29.1 | 41.6 | 44.4 | 25.7 | 5.4 |
| Base | 4,728 | 438 | 1,340 | 1,283 | 1,666 |
Contact
Email: Stuart King